IDH1- and IDH2-mutations in brain glial tumors — The new antioncogenic mechanism
Демяшкин Г. А., Никитин П. В.
Журнал неврологии и психиатрии им. C.C. Корсакова
Т. 118, Вып. 4, С. 134-139
Опубликовано: 2018
Тип ресурса: Обзор
DOI:10.17116/jnevro201811841134-139
Аннотация:
Mutant forms of the gene IDH1 progress significantly slower, have a lower risk of neoplastic transformation, and generally, mutations of this gene have a pronounced anti-oncogenic effect. At the same time, almost all mutations are quite stereotyped (98,9[%]) and occur in the same region of the gene — R132H mutations. IDH1 gene mutations is a complex multi-layered process, which is a completely new, not previously described anti-oncogene activation mechanism of intracellular protection. The reason that there is a mutation in the tumor cells is associated with de novo blocking differentiation processes and development of brain cells in the development process, as evidenced by severe cerebral hypoplasia in patients with congenital forms of this mutation. A completely new mechanism of antitumor protection has been described — stereotypical IDH1 gene mutation is a gene, in fact, is a key event, causing a cascade of further anti-oncogenic mechanisms in brain gliomas. © 2018, Media Sphera Publi
Ключевые слова:
Astrocytic gliomas; IDH1; IDH2
antineoplastic agent; IDH1 protein, human; isocitrate dehydrogenase; isocitrate dehydrogenase 2, human; antineoplastic activity; cell differentiation; gene; gene mutation; glioma; hypoplasia; idh1 gene; idh2 gene; oncogene; Review; tumor cell; brain; brain tumor; genetics; human; mutation; Brain; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Mutation
Язык текста: Русский
ISSN: 2309-4729
Демяшкин Г. А. Григорий Александрович 1976-
Никитин П. В.
Demyashkin G. A. Grigorij Aleksandrovich 1976-
Nikitin P. V.
IDH1- and IDH2-mutations in brain glial tumors — The new antioncogenic mechanism
Текст визуальный непосредственный
Журнал неврологии и психиатрии им. C.C. Корсакова
Издательство Медиа Сфера
Т. 118, Вып. 4 С. 134-139
2018
Обзор
Astrocytic gliomas IDH1 IDH2
antineoplastic agent IDH1 protein, human isocitrate dehydrogenase isocitrate dehydrogenase 2, human antineoplastic activity cell differentiation gene gene mutation glioma hypoplasia idh1 gene idh2 gene oncogene Review tumor cell brain brain tumor genetics human mutation Brain Brain Neoplasms Glioma Humans Isocitrate Dehydrogenase Mutation
Mutant forms of the gene IDH1 progress significantly slower, have a lower risk of neoplastic transformation, and generally, mutations of this gene have a pronounced anti-oncogenic effect. At the same time, almost all mutations are quite stereotyped (98,9[%]) and occur in the same region of the gene — R132H mutations. IDH1 gene mutations is a complex multi-layered process, which is a completely new, not previously described anti-oncogene activation mechanism of intracellular protection. The reason that there is a mutation in the tumor cells is associated with de novo blocking differentiation processes and development of brain cells in the development process, as evidenced by severe cerebral hypoplasia in patients with congenital forms of this mutation. A completely new mechanism of antitumor protection has been described — stereotypical IDH1 gene mutation is a gene, in fact, is a key event, causing a cascade of further anti-oncogenic mechanisms in brain gliomas. © 2018, Media Sphera Publi